CERE DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Cerevel Therapeutics Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - CERE

Core Viewpoint - Rosen Law Firm is reminding investors who sold or held shares of Cerevel Therapeutics Holdings, Inc. during a specified period about their potential entitlement to compensation through a class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the lawsuit is from October 11, 2023, to August 1, 2024, and includes those who held shares as of January 8, 2024, and those who sold shares around Bain Capital's purchase on October 16, 2023 [1]. - Investors may join the class action without incurring out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move to serve as lead plaintiff by June 3, 2025 [3]. Group 2: Case Allegations - The lawsuit alleges that during the class period, Cerevel's controlling shareholders made false and misleading statements related to a secondary stock offering on October 16, 2023, and a proxy statement on January 18, 2024 [5]. - The secondary stock offering was purportedly designed to allow Bain Capital to increase its stake in Cerevel at a discounted price before AbbVie Inc.'s acquisition announcement [5]. - Following the offering, AbbVie announced its acquisition of Cerevel for $45 per share, nearly double the offering price, resulting in Bain Capital receiving over $120 million in windfall profits [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements in the past, including over $438 million for investors in 2019 and has been ranked highly in securities class action settlements since 2013 [4].